These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31973910)

  • 1. Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.
    Fekete JT; Ősz Á; Pete I; Nagy GR; Vereczkey I; Győrffy B
    Gynecol Oncol; 2020 Mar; 156(3):654-661. PubMed ID: 31973910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.
    Pénzváltó Z; Lánczky A; Lénárt J; Meggyesházi N; Krenács T; Szoboszlai N; Denkert C; Pete I; Győrffy B
    BMC Cancer; 2014 Nov; 14():837. PubMed ID: 25408231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROCplot.org: Validating predictive biomarkers of chemotherapy/hormonal therapy/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients.
    Fekete JT; Győrffy B
    Int J Cancer; 2019 Dec; 145(11):3140-3151. PubMed ID: 31020993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
    Wu WJ; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes.
    Seborova K; Kloudova-Spalenkova A; Koucka K; Holy P; Ehrlichova M; Wang C; Ojima I; Voleska I; Daniel P; Balusikova K; Jelinek M; Kovar J; Rob L; Hruda M; Mrhalova M; Soucek P; Vaclavikova R
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer.
    Despierre E; Moisse M; Yesilyurt B; Sehouli J; Braicu I; Mahner S; Castillo-Tong DC; Zeillinger R; Lambrechts S; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I
    Gynecol Oncol; 2014 Dec; 135(3):415-22. PubMed ID: 25281495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer.
    Feng LY; Li L
    J Ovarian Res; 2020 Mar; 13(1):35. PubMed ID: 32228639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERCC5 is a novel biomarker of ovarian cancer prognosis.
    Walsh CS; Ogawa S; Karahashi H; Scoles DR; Pavelka JC; Tran H; Miller CW; Kawamata N; Ginther C; Dering J; Sanada M; Nannya Y; Slamon DJ; Koeffler HP; Karlan BY
    J Clin Oncol; 2008 Jun; 26(18):2952-8. PubMed ID: 18565881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
    Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
    Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Jeleniewicz W; Cybulski M; Nowakowski A; Stenzel-Bembenek A; Guz M; Marzec-Kotarska B; Kotarski J; Stepulak A
    Anticancer Res; 2019 Apr; 39(4):1821-1827. PubMed ID: 30952722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer.
    Mase S; Shinjo K; Totani H; Katsushima K; Arakawa A; Takahashi S; Lai HC; Lin RI; Chan MWY; Sugiura-Ogasawara M; Kondo Y
    Cancer Sci; 2019 Mar; 110(3):1105-1116. PubMed ID: 30633424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.
    Soto JA; Rodríguez-Antolín C; Vera O; Pernía O; Esteban-Rodríguez I; Dolores Diestro M; Benitez J; Sánchez-Cabo F; Alvarez R; De Castro J; Ibanez de Cáceres I
    Clin Epigenetics; 2021 Aug; 13(1):167. PubMed ID: 34454589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
    Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of CETN2 is associated with platinum resistance and poor prognosis in epithelial ovarian cancer.
    Qiu PY; Deng XH; Li L
    Clin Transl Oncol; 2023 May; 25(5):1340-1352. PubMed ID: 36527574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer.
    Nie S; Wan Y; Wang H; Liu J; Yang J; Sun R; Meng H; Ma X; Jiang Y; Cheng W
    J Ovarian Res; 2021 Sep; 14(1):115. PubMed ID: 34474677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Zhang GN; Liu H; Huang JM; Wang L; Zhao JS; Li C; Mi K; Zhu Y; Cheng J; Zha X
    Gynecol Oncol; 2014 Mar; 132(3):752-7. PubMed ID: 24463159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
    Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
    Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 3-gene biomarker signature to predict response to taxane-based neoadjuvant chemotherapy in breast cancer.
    Kallarackal J; Burger F; Bianco S; Romualdi A; Schad M
    PLoS One; 2020; 15(3):e0230313. PubMed ID: 32196521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.